Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer
Identifieur interne : 006F89 ( Ncbi/Curation ); précédent : 006F88; suivant : 006F90Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer
Auteurs : V. Pernin ; L. Belin ; P. Cottu ; P. Bontemps ; C. Lemanski ; B. De La Lande ; P. Baumann ; F. Missohou ; C. Levy ; K. Peignaux ; A. Reynaud-Bougnoux ; F. Denis ; A. Gobillion ; M. Bollet ; N A Vago ; R. Dendale ; F. Campana ; A. Fourquet ; Y M KirovaSource :
- The British Journal of Radiology [ 0007-1285 ] ; 2015.
Abstract
To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC).
Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT.
From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1–2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%).
The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC.
The largest series of this association.
Url:
DOI: 10.1259/bjr.20140800
PubMed: 25645108
PubMed Central: 4651262
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000256
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000256
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001140
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :006F89
Links to Exploration step
PMC:4651262Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer</title>
<author><name sortKey="Pernin, V" sort="Pernin, V" uniqKey="Pernin V" first="V" last="Pernin">V. Pernin</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cottu, P" sort="Cottu, P" uniqKey="Cottu P" first="P" last="Cottu">P. Cottu</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bontemps, P" sort="Bontemps, P" uniqKey="Bontemps P" first="P" last="Bontemps">P. Bontemps</name>
<affiliation><nlm:aff id="aff4"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lemanski, C" sort="Lemanski, C" uniqKey="Lemanski C" first="C" last="Lemanski">C. Lemanski</name>
<affiliation><nlm:aff id="aff5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="De La Lande, B" sort="De La Lande, B" uniqKey="De La Lande B" first="B" last="De La Lande">B. De La Lande</name>
<affiliation><nlm:aff id="aff6"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Baumann, P" sort="Baumann, P" uniqKey="Baumann P" first="P" last="Baumann">P. Baumann</name>
<affiliation><nlm:aff id="aff7"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Missohou, F" sort="Missohou, F" uniqKey="Missohou F" first="F" last="Missohou">F. Missohou</name>
<affiliation><nlm:aff id="aff8"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Levy, C" sort="Levy, C" uniqKey="Levy C" first="C" last="Levy">C. Levy</name>
<affiliation><nlm:aff id="aff9"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Peignaux, K" sort="Peignaux, K" uniqKey="Peignaux K" first="K" last="Peignaux">K. Peignaux</name>
<affiliation><nlm:aff id="aff10"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reynaud Bougnoux, A" sort="Reynaud Bougnoux, A" uniqKey="Reynaud Bougnoux A" first="A" last="Reynaud-Bougnoux">A. Reynaud-Bougnoux</name>
<affiliation><nlm:aff id="aff11"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Denis, F" sort="Denis, F" uniqKey="Denis F" first="F" last="Denis">F. Denis</name>
<affiliation><nlm:aff id="aff12"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bollet, M" sort="Bollet, M" uniqKey="Bollet M" first="M" last="Bollet">M. Bollet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vago, N A" sort="Vago, N A" uniqKey="Vago N" first="N A" last="Vago">N A Vago</name>
<affiliation><nlm:aff id="aff13"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25645108</idno>
<idno type="pmc">4651262</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651262</idno>
<idno type="RBID">PMC:4651262</idno>
<idno type="doi">10.1259/bjr.20140800</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">000256</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000256</idno>
<idno type="wicri:Area/Pmc/Curation">000256</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000256</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001140</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001140</idno>
<idno type="wicri:Area/Ncbi/Merge">006F89</idno>
<idno type="wicri:Area/Ncbi/Curation">006F89</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer</title>
<author><name sortKey="Pernin, V" sort="Pernin, V" uniqKey="Pernin V" first="V" last="Pernin">V. Pernin</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Belin, L" sort="Belin, L" uniqKey="Belin L" first="L" last="Belin">L. Belin</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cottu, P" sort="Cottu, P" uniqKey="Cottu P" first="P" last="Cottu">P. Cottu</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bontemps, P" sort="Bontemps, P" uniqKey="Bontemps P" first="P" last="Bontemps">P. Bontemps</name>
<affiliation><nlm:aff id="aff4"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lemanski, C" sort="Lemanski, C" uniqKey="Lemanski C" first="C" last="Lemanski">C. Lemanski</name>
<affiliation><nlm:aff id="aff5"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="De La Lande, B" sort="De La Lande, B" uniqKey="De La Lande B" first="B" last="De La Lande">B. De La Lande</name>
<affiliation><nlm:aff id="aff6"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Baumann, P" sort="Baumann, P" uniqKey="Baumann P" first="P" last="Baumann">P. Baumann</name>
<affiliation><nlm:aff id="aff7"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Missohou, F" sort="Missohou, F" uniqKey="Missohou F" first="F" last="Missohou">F. Missohou</name>
<affiliation><nlm:aff id="aff8"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Levy, C" sort="Levy, C" uniqKey="Levy C" first="C" last="Levy">C. Levy</name>
<affiliation><nlm:aff id="aff9"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Peignaux, K" sort="Peignaux, K" uniqKey="Peignaux K" first="K" last="Peignaux">K. Peignaux</name>
<affiliation><nlm:aff id="aff10"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reynaud Bougnoux, A" sort="Reynaud Bougnoux, A" uniqKey="Reynaud Bougnoux A" first="A" last="Reynaud-Bougnoux">A. Reynaud-Bougnoux</name>
<affiliation><nlm:aff id="aff11"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Denis, F" sort="Denis, F" uniqKey="Denis F" first="F" last="Denis">F. Denis</name>
<affiliation><nlm:aff id="aff12"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gobillion, A" sort="Gobillion, A" uniqKey="Gobillion A" first="A" last="Gobillion">A. Gobillion</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bollet, M" sort="Bollet, M" uniqKey="Bollet M" first="M" last="Bollet">M. Bollet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vago, N A" sort="Vago, N A" uniqKey="Vago N" first="N A" last="Vago">N A Vago</name>
<affiliation><nlm:aff id="aff13"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dendale, R" sort="Dendale, R" uniqKey="Dendale R" first="R" last="Dendale">R. Dendale</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Campana, F" sort="Campana, F" uniqKey="Campana F" first="F" last="Campana">F. Campana</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Fourquet, A" sort="Fourquet, A" uniqKey="Fourquet A" first="A" last="Fourquet">A. Fourquet</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kirova, Y M" sort="Kirova, Y M" uniqKey="Kirova Y" first="Y M" last="Kirova">Y M Kirova</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">The British Journal of Radiology</title>
<idno type="ISSN">0007-1285</idno>
<idno type="eISSN">1748-880X</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Objective:</title>
<p>To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC).</p>
</sec>
<sec><title>Methods:</title>
<p>Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT.</p>
</sec>
<sec><title>Results:</title>
<p>From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1–2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%).</p>
</sec>
<sec><title>Conclusion:</title>
<p>The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC.</p>
</sec>
<sec><title>Advances in knowledge:</title>
<p>The largest series of this association.</p>
</sec>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006F89 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 006F89 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Curation |type= RBID |clé= PMC:4651262 |texte= Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:25645108" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |